Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral azacitidine with or without vididencel maintenance for AML in first remission
ACTRN12624000738527Phase 2Recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vididencel and azacitidine in acute myeloid leukemia (AML), sponsored by Australasian Leukaemia & Lymphoma Group. Started Feb 2025; status: recruiting.
02
Drugs
vididencelazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12624000738527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000738527.